What is the clinical evidence that AChR antibodies cause Myasthenia Grevis?
More than 90% of patients with Myasthenia Grevis have circulating antibodies against nicotinic AChR.
Removal of the antibodies by plasmapheresis often improves the symptoms and signs of Myasthenia Grevis.
Decreased titers after therapy also may correlate with improved symptoms.
Favorable responses to immunotherapy are also consistent with autoimmune, antibody-mediated injury.
